On 15 October 2014, orphan designation (EU/3/14/1349) was granted by the European Commission to Voisin Consulting S.A.R.L., France, for recombinant human insulin receptor monoclonal antibody-fused-α-L-iduronidase for the treatment of mucopolysaccharidosis type I.
In October 2021, Voisin Consulting S.A.R.L. changed name to Voisin Consulting Life Sciences.
Recombinant human insulin receptor monoclonal antibody-fused-α-L-iduronidase
Treatment of mucopolysaccharidosis type I
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: